<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582646</url>
  </required_header>
  <id_info>
    <org_study_id>4705</org_study_id>
    <nct_id>NCT01582646</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain</brief_title>
  <acronym>Bêtapain</acronym>
  <official_title>Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropathic pain is due to a lesion or disease affecting the nervous system. Antidepressants
      (ADs) are recommended as the first line treatment. In a murine model, the investigators
      evidenced that antidepressants antiallodynic action is mediated through β2-adrenergic
      receptor stimulation and that β-mimetics display the same effect. These data support the idea
      that β-mimetics could offer a therapeutic alternative to ADs for neuropathic pain treatment.
      This study will aim at assessing the effects of terbutaline on neuropathic pain symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty of recruitment
  </why_stopped>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the average intensity of pain during the last 24 hours reported by the patient on a 11 points Numeric Scale</measure>
    <time_frame>Day one, day 14 and day 28 of each 4 weeks period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Postthoracotomy Pain</condition>
  <condition>Postthoracoscopy Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>first period with terbutaline and second period with placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>first period with placebo and second period with terbutaline.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline sustained release 5 mg</intervention_name>
    <description>Terbutaline 10mg oral per day (5 mg twice a day) during 28 days</description>
    <arm_group_label>first period with terbutaline and second period with placebo</arm_group_label>
    <arm_group_label>first period with placebo and second period with terbutaline.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults from 18 to 75 years old

          -  neuropathic painful condition following a thoracotomy or thoracoscopy for at least 3
             months

        Exclusion criteria:

          -  cardiovascular risk

          -  unstable diabetes mellitus

          -  allergy for terbutaline

          -  hypokaliemia without treatment

          -  untreated hypothyroidism

          -  HIV- or chemotherapy-induced neuropathy

          -  cancer being treated by chemo- or radio-therapy

          -  concomitant treatment with β-blockers, tricyclic ADs or morphine

          -  concomitant pain more severe than neuropathic pain- pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Muller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon,</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

